Checkmate Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger, by and among the company, Regeneron Pharmaceuticals, Inc. and Scandinavian Acquisition Sub, Inc. (Parent) and a wholly owned subsidiary of Parent (Purchaser), dated as of April 18, 2022. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, on May 31, 2022, Purchaser completed a cash tender offer (the Offer") to acquire all of the issued and outstanding shares of the common stock, par value $0.0001 per share, of the company at a price per share of $10.50, to be paid to the seller in cash, without interest and subject to reduction for any applicable withholding of taxes required by applicable law. In connection with the closing of the Merger, the ompany's Board of Directors appointed Robert E. Landry as Chief Financial Officer.